New Retina Radio
11.10.25
Could a biologic that addresses uveitic macular edema (UME) change the treatment landscape for uveitis patients? Rahul Khurana, MD, joins us to review data from the MEERKAT and SANDCAT trials assessing vamikibart (Genentech/Roche) for UME. And Arshad Khanani, MD, MA, joins us to review the open-label extension study of GATHER2. What effect does avacincaptad pegol (Izervay, Astellas) have 2 years after the initial study was completed? Join us to hear details about these late-breaking presentations from AAO 2025.
View full description +
Subscribe
11.10.25
Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLERahul Khurana, MD; and Arshad Khanani, MD, MA
11.06.25
AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt DiseasePeter Kaiser, MD; and Michel Michaelides, MD
11.03.25
The Nuts and Bolts of GA Therapy: The Discussions ContinueCharles Wykoff, MD, PhD; Hasenin Al-khersan, MD; and Nakul Singh, MD
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
10.23.25
Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDRAllen Ho, MD; and Charles Wykoff, MD, PhD
Editorially independent content, supported by Genentech.
10.10.25
New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient CareNiki Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD
Editorially Independent Content Supported by Genentech
10.09.25
The Nuts and Bolts of GA Therapy: The Opening SessionsCharles Wykoff, MD, PhD; with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
10.02.25
Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring VisionJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and PhotobiomodulationJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
Show More